Department of Endocrinology and Metabolism, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000 Zhejiang, China.
Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China.
J Diabetes Res. 2022 Nov 4;2022:2229139. doi: 10.1155/2022/2229139. eCollection 2022.
Few studies have specifically observed the relationship of sarcopenia, visceral obesity, or their joint effects with lean NAFLD in patients with diabetes. We aimed to investigate the associations of lean NAFLD with sarcopenia, visceral obesity, and sarcopenic visceral obesity (SV) in Chinese patients with type 2 diabetes mellitus (T2DM).
Altogether, 1,112 T2DM patients with BMI <25 kg/m were enrolled, and 33.18% of them were diagnosed with lean NAFLD by abdominal ultrasonography. Body composition markers were measured by bioelectrical impedance (BIA). Skeletal muscle mass index (SMI) was calculated as appendicular skeletal muscle mass (ASM) divided by weight, and sarcopenia was defined as SMI < 1 standard deviation (SD) below the sex-specific average for a young reference population. Visceral obesity was defined as visceral fat area (VFA) ≥ 100 cm. Participants were categorized into one of the four body composition groups: nonsarcopenia/nonvisceral obesity (NN), nonsarcopenia/visceral obesity (NV), sarcopenia/nonvisceral obesity (SN), and SV.
Compared to those in the NN group, patients in the NV and SN groups had a higher risk of lean NAFLD after full adjustments (NV: OR = 1.74; 95% CI: 1.09, 2.78; SN: OR =2.07; 95% CI: 1.23, 3.46). Of note, patients in the SV group had the highest odds of lean NAFLD (OR = 3.29; 95% CI: 2.10, 5.17). There were no significant interaction effects between sarcopenia and metabolic risk factors on prevalent lean NAFLD.
The current study demonstrated that SV was more closely associated with higher prevalent lean NAFLD than sarcopenia or visceral obesity alone in Chinese patients with T2DM. Besides, the harmful effect of sarcopenia on lean NAFLD was not influenced by visceral obesity or other metabolic risk factors. We hypothesize that increasing skeletal muscle mass more than just reducing visceral fat might be more optimal for the prevention and management of lean NAFLD, which needs further investigation in future studies.
很少有研究专门观察肌少症、内脏肥胖或它们联合效应对糖尿病患者非酒精性脂肪肝伴正常体重(lean NAFLD)的关系。我们旨在研究中国 2 型糖尿病(T2DM)患者中 lean NAFLD 与肌少症、内脏肥胖以及肌少症合并内脏肥胖(SV)的关系。
共纳入 1112 例 BMI<25kg/m2 的 T2DM 患者,其中 33.18%的患者通过腹部超声诊断为 lean NAFLD。通过生物电阻抗(BIA)测量体成分标志物。骨骼肌质量指数(SMI)计算为四肢骨骼肌质量(ASM)除以体重,肌少症定义为 SMI 低于年轻参考人群性别特异性平均值 1 个标准差以下。内脏肥胖定义为内脏脂肪面积(VFA)≥100cm。参与者被分为以下四个体成分组之一:非肌少症/非内脏肥胖(NN)、非肌少症/内脏肥胖(NV)、肌少症/非内脏肥胖(SN)和 SV。
与 NN 组相比,NV 和 SN 组患者在全调整后 lean NAFLD 的风险更高(NV:OR=1.74;95%CI:1.09,2.78;SN:OR=2.07;95%CI:1.23,3.46)。值得注意的是,SV 组患者 lean NAFLD 的可能性最高(OR=3.29;95%CI:2.10,5.17)。肌少症与代谢危险因素之间没有显著的交互作用影响 lean NAFLD 的患病率。
本研究表明,与肌少症或内脏肥胖单独相比,SV 与中国 T2DM 患者更高的 lean NAFLD 患病率更密切相关。此外,肌少症对 lean NAFLD 的有害影响不受内脏肥胖或其他代谢危险因素的影响。我们假设增加骨骼肌质量比仅仅减少内脏脂肪可能更有利于 lean NAFLD 的预防和管理,这需要在未来的研究中进一步探讨。